Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: a test-negative case-control study

View ORCID ProfileF.A. Niessen, Mirjam J. Knol, Susan J.M. Hahné, VECTOR study group, M.J.M. Bonten, P.C.J.L. Bruijning-Verhagen
doi: https://doi.org/10.1101/2021.11.09.21266060
F.A. Niessen
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands
2Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F.A. Niessen
  • For correspondence: annabel.niessen@rivm.nl
Mirjam J. Knol
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands
2Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan J.M. Hahné
2Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.J.M. Bonten
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.C.J.L. Bruijning-Verhagen
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands
2Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Real-world vaccine effectiveness (VE) estimates are essential to identify potential groups at higher risk of break-through infections and to guide policy. We assessed the VE of COVID-19 vaccination against COVID-19 hospitalization, while adjusting and stratifying for patient characteristics.

Methods We performed a test-negative case-control study in six Dutch hospitals. The study population consisted of adults eligible for COVID-19 vaccination hospitalized between May 1 and June 28 2021 with respiratory symptoms. Cases were defined as patients who tested positive for SARS-CoV-2 by PCR during the first 48 hours of admission or within 14 days prior to hospital admission. Controls were patients tested negative at admission and did not have a positive test during the 2 weeks prior to hospitalization. VE was calculated using multivariable logistic regression, adjusting for calendar week, sex, age, comorbidity and nursing home residency. Subgroup analysis was performed for age, sex and different comorbidities. Secondary endpoints were ICU-admission and mortality.

Results 379 cases and 255 controls were included of whom 157 (18%) were vaccinated prior to admission. Five cases (1%) and 40 controls (16%) were fully vaccinated (VE: 93%; 95% CI: 81 – 98), and 40 cases (11%) and 70 controls (27%) were partially vaccinated (VE: 70%; 95% CI: 50-82). A strongly protective effect of vaccination was found in all comorbidity subgroups. No ICU-admission or mortality were reported among fully vaccinated cases. Of unvaccinated cases, mortality was 10% and 19% was admitted at the ICU

Conclusion COVID-19 vaccination provides a strong protective effect against COVID-19 related hospital admission, in patients with and without comorbidity.

Competing Interest Statement

FAN, MJK, SHMH, PCJLB have no relevant financial or non-financial interests to disclose. MJMB acts as paid consultant for Janssen Vaccines (chair of international study steering committee; payments to UMC Utrecht) (2017-), Merck Sharp & Dohme B.V. (advisory board; payments to UMC Utrecht) (2020-), Pfizer (advisory board; payments to UMC Utrecht) (2021) and AstraZeneca (advisory board; payments to UMC Utrecht (2021).

Funding Statement

This study has been funded by the National Institute of Public Health and the Environment, the Netherlands.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was assessed by the medical research ethics committee Utrecht and considered not to be subject to the Medical Research Involving Humans Subjects Act (WMO).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Due to the safeguarding of the privacy of the subjects, case-based data is not publicly available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 10, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: a test-negative case-control study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: a test-negative case-control study
F.A. Niessen, Mirjam J. Knol, Susan J.M. Hahné, VECTOR study group, M.J.M. Bonten, P.C.J.L. Bruijning-Verhagen
medRxiv 2021.11.09.21266060; doi: https://doi.org/10.1101/2021.11.09.21266060
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: a test-negative case-control study
F.A. Niessen, Mirjam J. Knol, Susan J.M. Hahné, VECTOR study group, M.J.M. Bonten, P.C.J.L. Bruijning-Verhagen
medRxiv 2021.11.09.21266060; doi: https://doi.org/10.1101/2021.11.09.21266060

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)